Sanofi (SNY) Liabilities from Discontinued Operations (2009 - 2026)
Sanofi (SNY) posted Liabilities from Discontinued Operations of 228985285.23 for Q2 2026, up 264.29% sequentially from 62858349.79 in Q4 2025, and up 10014.55% YoY from N/an in Q2 2025.
Sanofi (SNY) Liabilities from Discontinued Operations (2009 - 2026) Analysis & Trends
Sanofi has reported Liabilities from Discontinued Operations for 18 years, with the latest figure at 228985285.23 in Q2 2026.
- Quarterly Liabilities from Discontinued Operations rose 10014.55% year-over-year to 228985285.23 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 228985285.23 (up 10014.55% YoY) and the FY2025 annual result came in at 62858349.79, down 97.24% from the prior year.
- Liabilities from Discontinued Operations advanced to 228985285.23 in Q2 2026 per SNY's latest filing, from 62858349.79 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 2277176797.75 in Q4 2024 and troughed at 2263919.38 in Q2 2025.
- A 5-year average of 331738026.35 and a median of 29215083.1 in 2022 frame the typical range for Liabilities from Discontinued Operations.
- The sharpest annual moves came in 2024 and 2025: Liabilities from Discontinued Operations surged 16180.41% in 2024, then tumbled 97.24% in 2025.
- Over 5 years, Liabilities from Discontinued Operations stood at 10202473.65 in 2022, then soared by 37.1% to 13987218.82 in 2023, then soared by 16180.41% to 2277176797.75 in 2024, then tumbled by 97.24% to 62858349.79 in 2025, then soared by 264.29% to 228985285.23 in 2026.
- According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered 228985285.23, 62858349.79, and 2263919.38 for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.99 Mn |
| Jun 30, 2026 | 228.99 Mn |
| Dec 31, 2025 | 62.86 Mn |
| Dec 31, 2025 | 62.86 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.28 Bn |
| Dec 31, 2024 | 2.28 Bn |
| Dec 31, 2023 | 13.99 Mn |
| Dec 31, 2023 | 13.99 Mn |
| Jun 30, 2023 | 40.29 Mn |
| Jun 30, 2023 | 40.29 Mn |
| Dec 31, 2022 | 10.20 Mn |
| Dec 31, 2022 | 10.20 Mn |
| Jun 30, 2022 | 18.14 Mn |
| Jun 30, 2022 | 18.14 Mn |
| Jun 30, 2021 | 21.68 Mn |
| Jun 30, 2021 | 21.68 Mn |
| Dec 31, 2020 | 38.15 Mn |
| Dec 31, 2020 | 38.15 Mn |